Ei Itobayashi

29PUBLICATIONS
150CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersHaematologyInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Jul 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

|Jul 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

|Jun 08, 2026
Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions.

|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

|May 11, 2026
Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

|Apr 21, 2026
Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

Pageof 5

Frequent Collaborators

26 joint publications

Hidenori Toyoda

25 joint publications

Toru Ishikawa

24 joint publications

Kunihiko Tsuji

23 joint publications

Toshifumi Tada